The p16INK4a/CDKN2A tumor suppressor and its relatives.
暂无分享,去创建一个
[1] Ken Chen,et al. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.
[2] Yue Xiong,et al. ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.
[3] G. Peters,et al. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts , 1998, Current Biology.
[4] Philip Smith,et al. Retinoblastoma and p16 proteins in mammary carcinoma: Their relationship to cyclin D1 and histopathological parameters , 1998, International journal of cancer.
[5] D. Stoppa-Lyonnet,et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. , 1998, Human molecular genetics.
[6] M. Haas,et al. Independent induction of senescence by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[7] G. Peters,et al. Ankyrin for clues about the function 0fp16INK4a , 1998, Nature Structural Biology.
[8] H. J. Kim,et al. Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4. , 1998, Molecular cell.
[9] R. Medema,et al. p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases , 1998, Oncogene.
[10] Bernard Ducommun,et al. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells , 1998, Oncogene.
[11] K. Hemminki,et al. Mutations in the CDKN2A ( p16INK4a ) gene in microdissected sporadic primary melanomas , 1998, International journal of cancer.
[12] S. Srivastava,et al. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells , 1998, Oncogene.
[13] L. Hengst,et al. Effects of p21Cip1/Waf1 at Both the G1/S and the G2/M Cell Cycle Transitions: pRb Is a Critical Determinant in Blocking DNA Replication and in Preventing Endoreduplication , 1998, Molecular and Cellular Biology.
[14] P. Pollock,et al. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds , 1997, Oncogene.
[15] N. Hayward,et al. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. , 1997, Cancer research.
[16] Richard A. Ashmun,et al. Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.
[17] S. Miyoshi,et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma , 1997, International journal of cancer.
[18] P. Pollock,et al. CDKN2A mutation in a non‐FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein , 1997, International journal of cancer.
[19] O. Bernard,et al. The human protein p19ARF is not detected in hemopoietic human cell lines that abundantly express the alternative β transcript of the p16INK4a/MTS1 gene , 1997, Oncogene.
[20] D. Bishop,et al. Germline mutations of the CDKN2 gene in UK melanoma families. , 1997, Human molecular genetics.
[21] P. Pollock,et al. CDKN2A/p16 is inactivated in most melanoma cell lines. , 1997, Cancer research.
[22] L. Chin,et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. , 1997, Genes & development.
[23] F. Zindy,et al. Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[24] Ernest D. Laue,et al. Structure of the cyclin-dependent kinase inhibitor p19Ink4d , 1997, Nature.
[25] W. Cavenee,et al. Functional analysis of wild-type and malignant glioma derived CDKN2Aβ alleles: Evidence for an RB-independent growth suppressive pathway , 1997, Oncogene.
[26] W. Yung,et al. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro , 1997, Oncogene.
[27] M. Volm,et al. Prognostic implications of cyclins (D1, E, A), cyclin‐dependent kinases (CDK2, CDK4) and tumor‐suppressor genes (pRb, p16INK4A) in childhood acute lymphoblastic leukemia , 1997, International journal of cancer.
[28] X. Liu,et al. G1 control gene status is frequently altered in resectable non‐small cell lung cancer , 1997, International journal of cancer.
[29] W. Hiddemann,et al. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. , 1997, Cancer research.
[30] P. Kleihues,et al. Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas , 1997, International journal of cancer.
[31] A. Franchi,et al. Cumulative prognostic value of p16/CDKN2 and p53 oncoprotein expression in premalignant laryngeal lesions. , 1997, Journal of the National Cancer Institute.
[32] G. Peters,et al. Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status , 1997, Oncogene.
[33] G. Mann,et al. Differential expression of p16INK4a and p16β transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations , 1997, Oncogene.
[34] M. Nistér,et al. Induction of senescence in human malignant glioma cells by p16INK4A , 1997, Oncogene.
[35] M. Laiho,et al. Cloning and characterization of p10, an alternatively spliced form of p15 cyclin-dependent kinase inhibitor. , 1997, Cancer research.
[36] F. Zindy,et al. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging , 1997, Oncogene.
[37] H. Koeffler,et al. The p19INK4D Cyclin dependent kinase inhibitor gene is altered in osteosarcoma , 1997, Oncogene.
[38] G. Thomas,et al. Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers , 1997, International journal of cancer.
[39] N. Hayward,et al. Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal. , 1997, The Journal of investigative dermatology.
[40] D. Wong,et al. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. , 1997, Cancer research.
[41] W. Farrell,et al. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. , 1997, Cancer research.
[42] Y. Collan,et al. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage , 1997, International journal of cancer.
[43] C. Moskaluk,et al. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. , 1997, Cancer research.
[44] P. Carroll,et al. Frequent homozygous deletion of cyclin‐dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization , 1997, Genes, chromosomes & cancer.
[45] J. Massagué,et al. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15 , 1997, Nature.
[46] M. Inganäs,et al. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. , 1997, Journal of the National Cancer Institute.
[47] M. Lung,et al. p16 tumor suppressor gene mutations in Chinese esophageal carcinomas in Hong Kong. , 1997, Cancer letters.
[48] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[49] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[50] S. Goodman,et al. Tumor-suppressive pathways in pancreatic carcinoma. , 1997, Cancer research.
[51] M. Tucker,et al. Affected members of melanoma‐prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF , 1997 .
[52] Y. Matsumura,et al. Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene. , 1997, Cancer letters.
[53] P. Yaswen,et al. Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells , 1997, Molecular and cellular biology.
[54] H. Koeffler,et al. Molecular analysis of the INK4 family of genes in prostate carcinomas. , 1997, The Journal of urology.
[55] T. Enomoto,et al. Alteration of p16 and p15 genes in common epithelial ovarian tumors , 1997, International journal of cancer.
[56] M. Ng,et al. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. , 1997, Blood.
[57] M. Malumbres,et al. Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas , 1997, Oncogene.
[58] S. Lowe,et al. Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.
[59] Y. Kubo,et al. Mutations of the INK4a locus in squamous cell carcinomas of human skin. , 1997, Biochemical and biophysical research communications.
[60] J. Benítez,et al. Hypermethylation of a 5′ CpG island of p16 is a frequent event in non-Hodgkin’s lymphoma , 1997, Leukemia.
[61] J. Bartek,et al. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death , 1997, Nature Medicine.
[62] P. Dirks,et al. Cyclin and Cyclin‐Dependent Kinase Expression in Human Astrocytoma Cell Lines , 1997, Journal of neuropathology and experimental neurology.
[63] J. Herman,et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. , 1997, Cancer research.
[64] J. Herman,et al. Frequent aberrant methylation of p16INK4a in primary rat lung tumors , 1997, Molecular and cellular biology.
[65] P. García-Miguel,et al. Mutational analysis of the p16 gene in human neuroblastomas , 1997, Molecular carcinogenesis.
[66] M. Link,et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. , 1997, Cancer research.
[67] K. Jeang,et al. Human T-cell leukemia virus type 1 Tax releases cell cycle arrest induced by p16INK4a , 1997, Journal of virology.
[68] C. Bartram,et al. Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes. , 1997, Leukemia research.
[69] N. Wake,et al. Alterations of the p16INK4A gene in human ovarian cancers , 1997, Molecular carcinogenesis.
[70] O. Yoshida,et al. Concomitant Presence of p16/Cyclin‐dependent Kinase 4 and Cyclin D/Cyclin‐dependent Kinase 4 omplexes in LNCaP Prostatic Cancer Cell Line , 1997, Japanese journal of cancer research : Gann.
[71] A. Feinberg,et al. Lack of imprinting of three human cyclin-dependent kinase inhibitor genes. , 1997, Cancer research.
[72] B. Leggett,et al. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population , 1997, Hepatology.
[73] K. Shigemasa,et al. p16 Overexpression: A Potential Early Indicator of Transformation in Ovarian Carcinoma , 1997, The Journal of the Society for Gynecologic Investigation: JSGI.
[74] V. Álvarez,et al. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. , 1997, Journal of clinical pathology.
[75] J. Boyd,et al. p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan. , 1997, The Journal of urology.
[76] J. Yokota,et al. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma. , 1997, Cancer research.
[77] R. Maestro,et al. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression , 1997, International journal of cancer.
[78] A. Olshan,et al. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV , 1997, Oncogene.
[79] M. Cummings,et al. Increased expression of cyclin‐dependent kinase inhibitor 2 (CDKN2A) gene product P16 INK4A in ovarian cancer is associated with progression and unfavourable prognosis , 1997, International journal of cancer.
[80] J. Massagué,et al. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. , 1997, Genes & development.
[81] M. Imamura,et al. Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b) genes in 30 esophageal squamous‐cell‐carcinoma cell lines , 1997, International journal of cancer.
[82] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[83] W. Cavenee,et al. Point mutations can inactivate in vitro and in vivo activities of p16INK4a/CDKN2A in human glioma , 1997, Oncogene.
[84] G. Gaidano,et al. Multigenetic lesions in infant acute leukaemias: correlations with ALL‐1 gene status , 1997, British journal of haematology.
[85] K. Hemminki,et al. Loss of heterozygosity and microsatellite instability in larynx cancer. , 1997, International journal of oncology.
[86] J. Minna,et al. Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. , 1997, Cancer research.
[87] A. Marchetti,et al. Alterations of P16 (MTS1) in node‐positive non‐small cell lung carcinomas , 1997, The Journal of pathology.
[88] H. Tsuda,et al. Decreased expression of the p16/MTS1 gene without mutation is frequent in human urinary bladder carcinomas. , 1997, Japanese journal of clinical oncology.
[89] R. Schneider-Stock,et al. Loss of heterozygosity on chromosome 9q21 (p16 gene) uncommon in soft‐tissue sarcomas , 1997, Molecular carcinogenesis.
[90] G. Landberg,et al. Telomerase activity is associated with cell cycle deregulation in human breast cancer. , 1997, Cancer research.
[91] K. Wills,et al. Rb functions to inhibit apoptosis during myocyte differentiation. , 1997, Cancer research.
[92] D. Grandér,et al. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines , 1997, Oncogene.
[93] D. Quelle,et al. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[94] R. Baumgartner,et al. NMR structural characterization of the CDK inhibitor p19INK4d , 1997, FEBS letters.
[95] H. W. Chang,et al. Loss of expression of the p16 gene is frequent in malignant skin tumors. , 1997, Biochemical and biophysical research communications.
[96] Carl W. Miller,et al. Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma , 1997, British journal of haematology.
[97] K. Kitagawa,et al. Increased Radiosensitivity of p16 Gene‐deleted Human Glioma Cells after Transfection with Wild‐type p16 Gene , 1997, Japanese journal of cancer research : Gann.
[98] M. Miwa,et al. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors , 1996, International journal of cancer.
[99] H. Dosaka-akita,et al. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. , 1996, Cancer research.
[100] G. Capellá,et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. , 1996, Cancer research.
[101] C. Sherr. Cancer Cell Cycles , 1996, Science.
[102] R. Kerbel,et al. TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1. , 1996, Oncogene.
[103] J. Bartek,et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. , 1996, Cancer research.
[104] P. Chaubert,et al. InformativeMspI polymorphism adjacent to exon 3 of thep16INK4(MTS1)gene , 1996 .
[105] J. Bartek,et al. The retinoblastoma protein pathway and the restriction point. , 1996, Current opinion in cell biology.
[106] M. Ivan,et al. Abnormalities of theP16INK4A gene in thyroid cancer cell lines , 1996 .
[107] O. Olopade,et al. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[108] M. Tomonaga,et al. Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies. , 1996, Leukemia.
[109] D. Bostwick,et al. Absence of p16/MTS1 gene mutations in human prostate cancer. , 1996, Carcinogenesis.
[110] A. Okamoto,et al. Molecular analysis of the cyclin‐dependent kinase inhibitor genes p15INK4b/MTS21, p16INK4/MTS1, p18 and pl9 in human cancer cell lines , 1996, International journal of cancer.
[111] G. Hannon,et al. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[112] B. Zhang,et al. Defective Folding of Mutant p16INK4 Proteins Encoded by Tumor-derived Alleles* , 1996, The Journal of Biological Chemistry.
[113] P. Heinzel,et al. Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers , 1996, International journal of cancer.
[114] P. Meltzer,et al. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. , 1996, Cancer research.
[115] C. Cordon-Cardo,et al. Establishment, characterization and drug sensitivity of four new human soft tissue sarcoma cell lines , 1996, International journal of cancer.
[116] R. Nairn,et al. A CDKN2-like polymorphism in Xiphophorus LG V is associated with UV-B-induced melanoma formation in platyfish-swordtail hybrids. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[117] N. Pavletich,et al. Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2 , 1996, Science.
[118] Y. Xiong,et al. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors. , 1996, Oncogene.
[119] Marshall W. Anderson,et al. Homozygous codeletion and differential decreased expression of p15INK4b, p16INK4a-alpha and p16INK4a-beta in mouse lung tumor cells. , 1996, Oncogene.
[120] Carissa A. Sanchez,et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. , 1996, Oncogene.
[121] J. Roth,et al. Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. , 1996, Cancer gene therapy.
[122] B. Quesnel,et al. Transfer of p16inka/CDKN2 gene in leukaemic cell lines inhibits cell proliferation , 1996, British journal of haematology.
[123] K. Chang,et al. MTS1 gene mutations in archival oral squamous cell carcinomas. , 1996, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[124] M. Bulyk,et al. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. , 1996, Cancer research.
[125] A. Kyritsis,et al. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. , 1996, Oncogene.
[126] A. Olshan,et al. Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. , 1996, Journal of the National Cancer Institute.
[127] M. Diccianni,et al. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. , 1996, Blood.
[128] J. Lapointe,et al. A p18 mutant defective in CDK6 binding in human breast cancer cells. , 1996, Cancer research.
[129] M. Rhyu,et al. Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population. , 1996, Cancer research.
[130] J. Schalken,et al. Homozygous deletions of p16INK4 occur frequently in bilharziasis‐associated bladder cancer , 1996, International journal of cancer.
[131] K. Kunishio,et al. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. , 1996, Journal of neuropathology and experimental neurology.
[132] A. Arnold,et al. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. , 1996, The Journal of clinical endocrinology and metabolism.
[133] K. Anderson,et al. A novel pre-B acute lymphoblastic leukemia cell line with chromosomal translocation between p16(INK4A)/p15(INK4B) tumor suppressor and immunoglobulin heavy chain genes: TGFbeta/IL-7 inhibitory signaling mechanism. , 1996, Leukemia.
[134] Hsiu‐Po Wang,et al. Intragenic Homozygous Deletions of MTS1 Gene in Gastric Cancer in Taiwan , 1996, Japanese journal of cancer research : Gann.
[135] D. Franklin,et al. Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. , 1996, Molecular biology of the cell.
[136] J. Foekens,et al. Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours. , 1996, British Journal of Cancer.
[137] M. Esumi,et al. Activation but not inactivation of the MTS1 gene is associated with primary colorectal carcinomas. , 1996, Biochemical and biophysical research communications.
[138] D. Sidransky,et al. p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. , 1996, Cancer research.
[139] V P Collins,et al. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. , 1996, Oncogene.
[140] J. Herman,et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[141] T. Kinoshita,et al. The CDKN2 gene alterations in various types of adult T‐cell leukaemia , 1996, British journal of haematology.
[142] H. Antoniades,et al. Cell-cycle regulator cyclin D1 mRNA and protein overexpression occurs in primary malignant gliomas. , 1996, International journal of oncology.
[143] S. Hirohashi,et al. Inactivation of p16INK4 in hepatocellular carcinoma , 1996, Hepatology.
[144] T. Norberg,et al. Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases. , 1996, British Journal of Cancer.
[145] H. Koga,et al. A Comparative Study of Glioma Cell Lines for p16, p15, p53 and p21 Gene Alterations , 1996, Japanese journal of cancer research : Gann.
[146] E. Healy,et al. Infrequent mutation of p16INK4 in sporadic melanoma. , 1996, The Journal of investigative dermatology.
[147] S. Nishizuka,et al. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. , 1996, Cancer research.
[148] R. Fairman,et al. Structural characterization of the tumor suppressor p16, an ankyrin‐like repeat protein , 1996, Protein science : a publication of the Protein Society.
[149] M. Beckmann,et al. Frequent allele loss on 9p21–22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer , 1996, Genes, chromosomes & cancer.
[150] J. Bartek,et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. , 1996, Cancer research.
[151] K. Isselbacher,et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[152] D. Niewoehner,et al. Rb and p16INK4a expression in resected non-small cell lung tumors. , 1996, Cancer research.
[153] M. Stanley,et al. Association of CDKN2A/p16INK4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. , 1996, Oncogene.
[154] H. Yokozaki,et al. Genetic Status and Expression of the Cyclin‐dependent Kinase Inhibitors in Human Gastric Carcinoma Cell Lines , 1996, Japanese journal of cancer research : Gann.
[155] F. Dammacco,et al. p16 gene analysis in multiple myeloma (MM). , 1996, Leukemia.
[156] A. Saxena,et al. Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas. , 1996, Oncogene.
[157] A. Elefanty,et al. Expression of the tumour suppressor genes p15 and p16 in malignant melanoma , 1996, Melanoma research.
[158] D. Carson,et al. Identification of human tumour suppressor genes by monochromosome transfer: rapid growth-arrest response mapped to 9p21 is mediated solely by the cyclin-D-dependent kinase inhibitor gene, CDKN2A (p16INK4A). , 1996, Carcinogenesis.
[159] V. Kraynov,et al. Tumor Suppressor p16INK4A: Structural Characterization of Wild-Type and Mutant Proteins by NMR and Circular Dichroism† , 1996 .
[160] K. Walsh,et al. Resistance to Apoptosis Conferred by Cdk Inhibitors During Myocyte Differentiation , 1996, Science.
[161] J. Block,et al. Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas. , 1996, Cancer letters.
[162] J. Block,et al. Partial deletions of the CDKN2 and MTS2 putative tumor suppressor genes in a myxoid chondrosarcoma. , 1996, Cancer letters.
[163] N. Nishida,et al. Infrequent alterations of the p16INK4A gene in liver cancer , 1996, International journal of cancer.
[164] S. Tsunoda,et al. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas , 1996, Cancer.
[165] A. Kamb,et al. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. , 1996, Cancer research.
[166] M. Diccianni,et al. The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance. , 1996, Cancer letters.
[167] Ciro Mercurio,et al. Biochemical Characterization of p16INK4- and p18-containing Complexes in Human Cell Lines* , 1996, The Journal of Biological Chemistry.
[168] O. Pereira-smith,et al. Replicative Senescence: Implications for in Vivo Aging and Tumor Suppression , 1996, Science.
[169] S. Lippman,et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment , 1996, Nature Medicine.
[170] A. Fusco,et al. Status and expression of the p16INK4 gene in human thyroid tumors and thyroid‐tumor cell lines , 1996, International journal of cancer.
[171] J. Geradts,et al. High frequency of aberrant p16(INK4A) expression in human breast cancer. , 1996, The American journal of pathology.
[172] R. Aguiar,et al. Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas , 1996, Clinical endocrinology.
[173] E. Shaw,et al. Genetic analysis of second primary lung cancers in patients surviving small cell lung cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[174] T. Kumanishi,et al. Primary Malignant Lymphoma of the Brain: Demonstration of Frequent p16 and p15 Gene Deletions , 1996, Japanese journal of cancer research : Gann.
[175] J. Schalken,et al. p16 mutations/deletions are not frequent events in prostate cancer. , 1996, British Journal of Cancer.
[176] Y. Hayashi,et al. Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)-negative but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood. , 1996, Leukemia.
[177] C. Reznikoff,et al. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. , 1996, Cancer research.
[178] S. Linder,et al. Expression of CDK inhibitor genes in immortalized and carcinoma derived breast cell lines. , 1996, Anticancer research.
[179] K. Sakata. Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma. , 1996, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[180] G. Peters,et al. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma , 1996, Molecular and cellular biology.
[181] S. Leung,et al. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. , 1996, Cancer research.
[182] S. Ogawa,et al. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. , 1996, Blood.
[183] P. Tran,et al. Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[184] E. Okajima,et al. Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers. , 1996, Cancer letters.
[185] C. James,et al. Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P 16ink4 homozygous deletions and CDK4 gene amplifications. , 1996, Journal of neurosurgery.
[186] J. Califano,et al. 11:40 AM: A Genetic Progression Model for Head and Neck Cancer: Implications for Field Cancerization , 1996 .
[187] K. Post,et al. Frequent loss of the P16INK4a gene product in human pituitary tumors. , 1996, Cancer research.
[188] F. Ragione,et al. p16INK4A gene homozygous deletions in human acute leukaemias with alterations of chromosome 9 , 1996, British journal of haematology.
[189] P. Jones,et al. DNA methylation errors and cancer. , 1996, Cancer research.
[190] Å. Borg,et al. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. , 1996, Cancer research.
[191] U. Kees,et al. Deletions of the p16 gene in pediatric leukemia and corresponding cell lines. , 1996, Oncogene.
[192] P. Goodfellow,et al. Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. , 1996, Journal of the National Cancer Institute.
[193] T. Fukui,et al. Allelotype analysis in mouse hepatocellular carcinomas; frequent homozygous deletion of mouse homolog of p16/CDKN2 gene on chromosome 4 in culture. , 1996, Biological & pharmaceutical bulletin.
[194] M. Berger,et al. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. , 1996, Cancer research.
[195] M. Hollstein,et al. Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas , 1996, International journal of cancer.
[196] P. Kleihues,et al. Infrequent alterations of the p15, p16, CDK4 and CYCLIN D1 genes in non‐astrocytic human brain tumors , 1996, International journal of cancer.
[197] K. Srivenugopal,et al. Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells. , 1996, Oncogene.
[198] D. Grandér,et al. Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[199] D. Grandér,et al. p16INK4/p15INK4B gene inactivation is a frequent event in malignant T‐cell lines , 1996, European journal of haematology.
[200] A. Okamoto,et al. Suppression of growth in vitro and tumorigenicity in vivo of human carcinoma cell lines by transfected p16INK4 , 1996, Molecular carcinogenesis.
[201] T. Kirita,et al. Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. , 1996, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[202] S. Tsunoda,et al. Immunohistochemical detection of CDKN2, retinoblastoma and p53 gene products in primary astrocytic tumors. , 1996, International journal of oncology.
[203] T. Urano,et al. Decreased expression of p16 gene in gastric cancer. , 1996, International journal of oncology.
[204] D. Sidransky. Cancer genetics: Two tracks but one race? , 1996, Current Biology.
[205] K. Riabowol,et al. Differential CDK-inhibitor gene expression in aging human diploid fibroblasts , 1996, Experimental Gerontology.
[206] J. Nevins,et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[207] K. Shimotohno,et al. Expression of cell-cycle regulatory genes in HTLV-I infected T-cell lines: possible involvement of Tax1 in the altered expression of cyclin D2, p18Ink4 and p21Waf1/Cip1/Sdi1. , 1996, Oncogene.
[208] E. Stanbridge,et al. Design of a novel bicistronic expression vector with demonstration of a p16INK4-induced G(1)-S block(1). , 1996, Cancer research.
[209] R. Sutherland,et al. Cancer‐associated mis‐sense and deletion mutations impair p16INK4 CDK inhibitory activity , 1996, International journal of cancer.
[210] L. Chin,et al. Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.
[211] M. Yoshida,et al. HTLV‐1 Tax protein interacts with cyclin‐dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. , 1996, The EMBO journal.
[212] W. Schmiegel,et al. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. , 1996, Gastroenterology.
[213] R. Jamal,et al. Variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level. , 1996, Leukemia.
[214] G. Basso,et al. Analysis of cyclin‐dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma , 1996, Genes, chromosomes & cancer.
[215] E. Hovig,et al. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. , 1996, British Journal of Cancer.
[216] S. Smith,et al. Deletion or lack of expression of CDKN2 (CDK4I/MTS1/INK4A) and MTS2 (INK4B) in acute lymphoblastic leukemia cell lines reflects the phenotype of the uncultured primary leukemia cells. , 1996, Leukemia.
[217] A. D. Dei Tos,et al. Tumor suppressor genes and related molecules in leiomyosarcoma. , 1996, The American journal of pathology.
[218] A. Rustgi,et al. p16 inhibition of transformed and primary squamous epithelial cells. , 1996, Oncogene.
[219] T. Ohnishi,et al. Lack of p16/CDKN2 alterations in thyroid carcinomas. , 1996, Cancer letters.
[220] B. Rollins,et al. p16INK4A as a human tumor suppressor. , 1996, Biochimica et biophysica acta.
[221] C. Shields,et al. Deletion mapping of chromosome region 9p21‐p22 surrounding the CDKN2 locus in melanoma , 1996, International journal of cancer.
[222] F. Sigaux,et al. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. , 1996, Blood.
[223] Qiang Wu,et al. Growth arrest and suppression of tumorigenicity of bladder carcinoma cell lines induced by the P16/CDKN2 (p16INK4A, MTS1) gene and other loci on human chromosome 9 , 1996, International journal of cancer.
[224] A. Okamoto,et al. Intragenic mutations of the p16INK4, p15INK4B and p18 genes in primary non‐small‐cell lung cancers , 1996 .
[225] S. Kawauchi,et al. Homozygous deletion of mouse homolog of p16/CDKN2 gene on chromosome 4 in mouse liver epithelial cells in culture. , 1996, Biological & pharmaceutical bulletin.
[226] D. Becker,et al. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system. , 1996, Oncogene.
[227] T. Goodrow,et al. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. , 1996, Cancer research.
[228] Z. Tang,et al. Alterations of CDKN2(p16/MTS1) exon 2 in human hepatocellular carcinoma. , 1996, Oncology reports.
[229] T. Savarese,et al. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. , 1996, Cancer research.
[230] N. Konishi,et al. Focal distribution of p16/CDKN2 gene mutations within individual prostate carcinomas. , 1996, International journal of oncology.
[231] G. Peters,et al. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence , 1996, Molecular and cellular biology.
[232] N. Hayward. The current situation with regard to human melanoma and genetic inferences. , 1996, Current opinion in oncology.
[233] D. Grandér,et al. Exclusive p15INK4B gene deletions in acute lymphocytic leukemia include the E1 beta exon of the p16INK4 gene. , 1996, Blood.
[234] J. Herman,et al. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. , 1996, Cancer research.
[235] H. Matsuda,et al. Inversely correlated expression of p16 and Rb protein in non‐small cell lung cancers: An immunohistochemical study , 1996, International journal of cancer.
[236] N. Cross,et al. Mutational analysis of the p15 and p16 genes in acute leukaemias , 1996, British journal of haematology.
[237] M. Inganäs,et al. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. , 1996, British Journal of Cancer.
[238] Y. Takeshima,et al. p16/CDKN2 Gene and p53 Gene Alterations in Japanese Non‐smoking Female Lung Adenocarcinoma , 1996, Japanese journal of cancer research : Gann.
[239] A. Iolascon,et al. Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias. , 1996, Leukemia.
[240] H. Koeffler,et al. Alterations of the p15, p16,and p18 genes in osteosarcoma. , 1996, Cancer genetics and cytogenetics.
[241] P. Pollock,et al. Compilation of somatic mutations of the CDKN2 gene in human cancers: Non‐random distribution of base substitutions , 1996, Genes, chromosomes & cancer.
[242] C. Bartram,et al. Molecular analysis of the cyclin‐dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas , 1996, Cancer.
[243] H. Kaneko,et al. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage. , 1996, Leukemia.
[244] R. Siebert,et al. Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines. , 1996, Leukemia research.
[245] E. Healy,et al. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. , 1996, Cancer research.
[246] H. Gabra,et al. High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. , 1996, British Journal of Cancer.
[247] M. Raffeld,et al. Absence of p18 mutations or deletions in lymphoid malignancies. , 1996, Leukemia.
[248] R. Fåhraeus,et al. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide from p16CDKN2/INK4A , 1996, Current Biology.
[249] Y. Xiong,et al. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors. , 1996, Oncogene.
[250] M. Schlumberger,et al. High frequency deletion of the tumour suppressor gene P16INK4a (MTS1) in human thyroid cancer cell lines , 1996, Molecular and Cellular Endocrinology.
[251] M. Serrano,et al. Analysis of p16INK4a and its interaction with CDK4. , 1996, Biochemical and biophysical research communications.
[252] J. Bruner,et al. Mutations of the p16 gene in gliomas. , 1996, Oncogene.
[253] J. Bruner,et al. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. , 1996, Oncogene.
[254] P. Goodfellow,et al. Infrequent CDKN2 mutation in human differentiated thyroid cancers , 1996, Molecular carcinogenesis.
[255] H. Cavé,et al. Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias , 1996, British journal of haematology.
[256] F. Kaye,et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. , 1995, Journal of the National Cancer Institute.
[257] A. Sigurdsson,et al. Loss of heterozygosity on chromosome 9 in human breast cancer: Association with clinical variables and genetic changes at other chromosome regions , 1995, International journal of cancer.
[258] R. Kratzke,et al. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. , 1995, Cancer research.
[259] F. Zindy,et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.
[260] C. D. Edwards,et al. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. , 1995, Cancer research.
[261] B. Peters,et al. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. , 1995, Oncogene.
[262] M. Skolnick,et al. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. , 1995, Oncogene.
[263] G. Finocchiaro,et al. Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas. , 1995, Biochemical and biophysical research communications.
[264] A. Kyritsis,et al. A frequent polymorphism in exon 1 of the p16/CDKN2 gene. , 1995, Molecular and cellular probes.
[265] A. Albino,et al. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. , 1995, Cancer research.
[266] O. Olopade,et al. CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B‐ and T‐cell origin but is frequent in acute lymphoblastic leukaemia , 1995, British journal of haematology.
[267] Carl W. Miller,et al. Molecular analysis of a family of cyclin‐dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non‐small cell lung cancers , 1995, Molecular carcinogenesis.
[268] T. Sekiya,et al. Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers , 1995, International journal of cancer.
[269] S. Wick,et al. Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16. , 1995, Oncogene.
[270] T. Sekiya,et al. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. , 1995, Oncogene.
[271] A. Balmain,et al. Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. , 1995, Cancer research.
[272] J. Epstein,et al. Partial allelotype of carcinoma in situ of the human bladder. , 1995, Cancer research.
[273] R. Sutherland,et al. Expression of the cyclin‐dependent kinase inhibitors p16INK4, p15INK4B and p21Waf1/cip1 in human breast cancer , 1995, International journal of cancer.
[274] Jian-ming Li,et al. Transforming Growth Factor β Activates the Promoter of Cyclin-dependent Kinase Inhibitor p15INK4B through an Sp1 Consensus Site (*) , 1995, The Journal of Biological Chemistry.
[275] T. Ohnishi,et al. Homozygous deletions of p16INK4A/MTS1 and p15INK4B/MTS2 genes in glioma cells and primary glioma tissues. , 1995, Cancer letters.
[276] M. Kelley,et al. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. , 1995, Oncogene.
[277] E. Newcomb,et al. Alterations of multiple tumor suppressor genes (p53 (17p13), p16INK4 (9p21), and DBM (13q14)) in B‐CELL chronic lymphocytic leukemia , 1995, Molecular carcinogenesis.
[278] F. Ragione,et al. Involvement of the cyclin‐dependent kinase‐4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia , 1995, British journal of haematology.
[279] A. Iolascon,et al. High frequency of homozygous deletions of CDK4I gene in childhood acute lymphoblastic leukaemia , 1995, British journal of haematology.
[280] J. Southgate,et al. Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines. , 1995, British Journal of Cancer.
[281] Jack A. Taylor,et al. Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors , 1995, Molecular carcinogenesis.
[282] B. Scheithauer,et al. Histopathology, classification, and grading of gliomas , 1995, Glia.
[283] J. Bartek,et al. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. , 1995, Cancer research.
[284] Carl W. Miller,et al. Alterations of CDKN2 (p16) in non‐small cell lung cancer , 1995, Genes, chromosomes & cancer.
[285] P. Goodfellow,et al. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas , 1995, Genes, chromosomes & cancer.
[286] J. Olson,et al. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. , 1995, Cancer research.
[287] S. Melmed,et al. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. , 1995, The Journal of urology.
[288] M. Ergazaki,et al. Loss of heterozygosity at 9p and 17q in human laryngeal tumors. , 1995, Cancer letters.
[289] G. Peters,et al. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. , 1995, Oncogene.
[290] G. Hannon,et al. Deletion of the p16 and p15 genes in human bladder tumors. , 1995, Journal of the National Cancer Institute.
[291] R. Beart,et al. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. , 1995, Cancer research.
[292] Y. Xiong,et al. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma , 1995 .
[293] J. Herman,et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.
[294] A M Goldstein,et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. , 1995, The New England journal of medicine.
[295] P. Goodfellow,et al. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. , 1995, The New England journal of medicine.
[296] J. Downing,et al. Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d, an inhibitor of cyclin D-dependent kinases. , 1995, Genomics.
[297] M. Hengstschläger,et al. Expression of the cyclin‐dependent kinase inhibitor p16 during the ongoing cell cycle , 1995, FEBS letters.
[298] W. Foulkes,et al. Loh and mutation analysis of CDKN2 in primary human ovarian cancers , 1995, International journal of cancer.
[299] F. Kaye,et al. CDKN2 in HPV‐positive and HPV‐negative cervical‐carcinoma cell lines , 1995, International journal of cancer.
[300] R. Berkowitz,et al. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. , 1995, Oncogene.
[301] M. Bar‐eli,et al. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. , 1995, Oncogene.
[302] T. Hudson,et al. Novel fluorescence in situ hybridization approaches in solid tumors. Characterization of frozen specimens, touch preparations, and cytological preparations. , 1995, The American journal of pathology.
[303] G. Hannon,et al. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. , 1995, Human molecular genetics.
[304] Kathleen R. Cho,et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.
[305] K. Uzawa,et al. Mutational state of p16/cdkn2 and vhl genes in squamous-cell carcinoma of the oral cavity. , 1995, International journal of oncology.
[306] J. Foekens,et al. Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. , 1995, British Journal of Cancer.
[307] R. Siebert,et al. Homozygous loss of the MTSl/pl6 and MTS2/pl5 genes in lymphoma and lymphoblastic leukaemia cell lines , 1995, British journal of haematology.
[308] N. Hayward,et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. , 1995, Human molecular genetics.
[309] T. Kinoshita,et al. Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas. , 1995, Blood.
[310] C Roskelley,et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[311] F. Kaye,et al. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. , 1995, Oncogene.
[312] A. Reymond,et al. p16 proteins from melanoma-prone families are deficient in binding to Cdk4. , 1995, Oncogene.
[313] C. Busch,et al. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. , 1995, Journal of the National Cancer Institute.
[314] L. Cooper,et al. Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocyte activation and neuronal differentiation. , 1995, Cancer research.
[315] L. Cannon-Albright,et al. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. , 1995, Oncogene.
[316] E. Musgrove,et al. Involvement of RB-1, p53, p16INK4 and telomerase in immortalisation of human cells. , 1995, Oncogene.
[317] O. Hino,et al. Molecular genetic basis of renal carcinogenesis in the Eker rat model of tuberous sclerosis(Tsc2) , 1995, Molecular carcinogenesis.
[318] M. Williamson,et al. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. , 1995, Human molecular genetics.
[319] M. Serrano,et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.
[320] Carl W. Miller,et al. Structural integrity of the cyclin‐dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias , 1995, British journal of haematology.
[321] E. Coto,et al. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[322] T. Hunter,et al. Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. , 1995, Molecular biology of the cell.
[323] R. Takahashi,et al. Contribution of Chromosome 9p21‐22 Deletion to the Progression of Human Renal Cell Carcinoma , 1995, Japanese journal of cancer research : Gann.
[324] G. Hannon,et al. Cloning and characterization of murine p16INK4a and p15INK4b genes. , 1995, Oncogene.
[325] P. Pollock,et al. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. , 1995, Oncogene.
[326] S. Ogawa,et al. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. , 1995, Blood.
[327] H. Koeffler,et al. Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas. , 1995, Blood.
[328] Y. Hayashi,et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. , 1995, Blood.
[329] J. Fletcher,et al. Codeletion of p15 and p16 in primary malignant mesothelioma. , 1995, Oncogene.
[330] K. Hoang-Xuan,et al. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. , 1995, Oncogene.
[331] X. Estivill,et al. Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. , 1995, American journal of human genetics.
[332] B. Quesnel,et al. Analysis of p16 gene deletion and point mutation in breast carcinoma. , 1995, British Journal of Cancer.
[333] S. Meltzer,et al. Genomic DNA and messenger rna expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines , 1995, Genes, chromosomes & cancer.
[334] P. Goodfellow,et al. Low frequency of CDKN2 mutation in endometrial carcinomas , 1995, Molecular carcinogenesis.
[335] H. Koeffler,et al. Role of the cyclin-dependent kinase inhibitors in the development of cancer. , 1995, Blood.
[336] J. Roth,et al. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. , 1995, Cancer research.
[337] E. Hovig,et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1. , 1995, British Journal of Cancer.
[338] A. Iavarone,et al. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. , 1995, Genes & development.
[339] T. Sugimura,et al. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. , 1995, Cancer research.
[340] K. Mimori,et al. Multiple tumor-suppressor-1 gene and esophageal-carcinoma. , 1995, International journal of oncology.
[341] J. Barrett,et al. Genetic analysis of cellular senescence. , 1995, Biochimica et biophysica acta.
[342] J. Slingerland,et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. , 1995, Oncogene.
[343] S. Tavtigian,et al. Complex structure and regulation of the P16 (MTS1) locus. , 1995, Cancer research.
[344] C. Bartram,et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. , 1995, Blood.
[345] C. D. Edwards,et al. A novel p16INK4A transcript. , 1995, Cancer research.
[346] J. Fletcher,et al. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. , 1995, Cancer research.
[347] R. Berger,et al. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. , 1995, Oncogene.
[348] R. Weinberg,et al. Growth suppression by p16ink4 requires functional retinoblastoma protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[349] O. Olopade,et al. Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[350] Hiroyoshi Suzuki,et al. Mutational Analysis of CDKN2 (CDK4I/MTS1) Gene in Tissues and Cell Lines of Human Prostate Cancer , 1995, Japanese journal of cancer research : Gann.
[351] J. Barrett,et al. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[352] J. Herman,et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.
[353] S. Hanai,et al. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. , 1995, Cancer research.
[354] C. Bréchot,et al. Alterations of cyclin-dependent kinase 4 inhibitor (p16INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias. , 1995, Leukemia.
[355] C. James,et al. Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia. , 1995, Leukemia.
[356] F. Haluska,et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.
[357] T. Manshouri,et al. p16INK4A and p15INK4B gene deletions in primary leukemias. , 1995, Blood.
[358] A. Brenner,et al. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. , 1995, Cancer research.
[359] L. Sandkuijl,et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds , 1995, Nature Genetics.
[360] H P Koeffler,et al. Mutational effects on the p16INK4a tumor suppressor protein. , 1995, Cancer research.
[361] A. Kaye,et al. Homozygous deletions of the MTS1 gene are rare in non-astrocytic brain tumors. , 1995, Biochemical and biophysical research communications.
[362] D. Grandér,et al. p15ink4B and p16ink4 gene inactivation in acute lymphocytic leukemia. , 1995, Blood.
[363] J. Bartek,et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 , 1995, Nature.
[364] B. Dynlacht,et al. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition , 1995, Nature.
[365] L. Sandkuijl,et al. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple‐mole melanoma (FAMMM) syndrome families , 1995, Melanoma research.
[366] R. Chaganti,et al. Homozygous Deletions and Loss of Expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors , 1995, Genes, chromosomes & cancer.
[367] G. Stein,et al. Origins of G1 arrest in senescent human fibroblasts , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.
[368] S. Steinberg,et al. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. , 1995, Journal of the National Cancer Institute.
[369] M. Tomonaga,et al. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. , 1995, Blood.
[370] F. Mandelli,et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. , 1995, Blood.
[371] James M. Roberts,et al. Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.
[372] J. Maris,et al. No CDKN2 mutations in neuroblastomas. , 1995, Cancer research.
[373] D. Huang,et al. p16 gene alterations in nasopharyngeal carcinoma. , 1995, Cancer research.
[374] K. Buetow,et al. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. , 1995, Cancer research.
[375] R. Weinberg,et al. The retinoblastoma protein and cell cycle control , 1995, Cell.
[376] S. Shurtleff,et al. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. , 1995, Blood.
[377] D N Shapiro,et al. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4 , 1995, Molecular and cellular biology.
[378] W Arap,et al. Loss of P16INK4 expression is frequent in high grade gliomas. , 1995, Cancer research.
[379] M. Roussel,et al. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6 , 1995, Molecular and cellular biology.
[380] J. Bartek,et al. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity , 1995, Molecular and cellular biology.
[381] H. Varmus,et al. Mutations associated with familial melanoma impair p16INK4 function , 1995, Nature Genetics.
[382] R. Eeles,et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. , 1995, The American journal of pathology.
[383] D. Louis,et al. The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor. , 1995, Neurosurgery.
[384] P. Carroll,et al. Chromosome‐9 loss detected by fluorescence in situ hybridization in bladder cancer , 1995, International journal of cancer.
[385] M. Serrano,et al. Association of rat p15INK4B/p16INK4 deletions with monosomy 5 in kidney epithelial cell lines but not primary renal tumors. , 1995, Cancer research.
[386] J. Goldman,et al. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. , 1995, Blood.
[387] G. Tamura,et al. Loss of Heterozygosity on the Short Arm of Chromosome 9 without p16 Gene Mutation in Gastric Carcinomas , 1995, Japanese journal of cancer research : Gann.
[388] M. Raffeld,et al. Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. , 1995, Cancer research.
[389] G. Hannon,et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. , 1995, Cancer research.
[390] S. Ogawa,et al. Frequent Loss of the Cyclin‐dependent Kinase‐4 Inhibitor Gene in Human Gliomas , 1995, Japanese journal of cancer research : Gann.
[391] J. Bartek,et al. Aberrations of p16Ink4 and retinoblastoma tumour‐suppressor genes occur in distinct sub‐sets of human cancer cell lines , 1995, International journal of cancer.
[392] W. Cavenee,et al. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. , 1995, Cancer research.
[393] David O. Morgan,et al. Principles of CDK regulation , 1995, Nature.
[394] P. Borgen,et al. Analysis of MTS1/CDK4 in female breast carcinomas. , 1995, Cancer letters.
[395] A. Iolascon,et al. 5'-Deoxy-5'-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines. , 1995, Oncogene.
[396] Yusuke Nakamura,et al. Infrequent Somatic Mutation of the MTS1 Gene in Primary Bladder Carcinomas , 1995, Japanese journal of cancer research : Gann.
[397] O. Olopade,et al. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. , 1995, Cancer research.
[398] B. Tycko,et al. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. , 1995, The American journal of pathology.
[399] A. Okamoto,et al. IS-12 Mutation and altered expression of P16^ in human cancer. , 1995 .
[400] A. Hildesheim,et al. No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas. , 1995, Oncogene.
[401] M. Yuille,et al. Deletions and rearrangement of CDKN2 in lymphoid malignancy. , 1995, Blood.
[402] A. Rustgi,et al. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. , 1995, Oncogene.
[403] C. D. Edwards,et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. , 1995, Cancer research.
[404] F. Sigaux,et al. Homozygous MTS1 (p16INK4A) deletion in primary tumor cells of 163 leukemic patients. , 1995, Blood.
[405] G. Peters,et al. Lack of cyclin D‐Cdk complexes in Rb‐negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. , 1995, The EMBO journal.
[406] R. Ueda,et al. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. , 1995, Cancer research.
[407] B. Quesnel,et al. p16 gene homozygous deletions in acute lymphoblastic leukemia. , 1995, Blood.
[408] O. Olopade,et al. Increased p16 levels correlate with pRb alterations in human urothelial cells. , 1995, Cancer research.
[409] D. Sidransky,et al. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. , 1995, Cancer research.
[410] R. DePinho,et al. Inhibition of ras-induced proliferation and cellular transformation by p16INK4 , 1995, Science.
[411] G. Finocchiaro,et al. Mutation rate of the CDKN2 gene in malignant gliomas. , 1994, Cancer research.
[412] F. Sigaux,et al. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. , 1994, Blood.
[413] K. Kinzler,et al. Deletion of p16 and p15 genes in brain tumors. , 1994, Cancer research.
[414] C. O'keefe,et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. , 1994, Genes & development.
[415] G. Reifenberger,et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.
[416] Jing Yin,et al. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. , 1994, Cancer research.
[417] J. A. Bishop,et al. Genetic heterogeneity in familial malignant melanoma. , 1994, Human molecular genetics.
[418] E. Lander,et al. Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. , 1994, Cancer research.
[419] W. A. Yeudall,et al. MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. , 1994, Carcinogenesis.
[420] M. Skolnick,et al. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). , 1994, Cancer research.
[421] J. Shay,et al. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. , 1994, Cancer research.
[422] Paul Nurse,et al. Ordering S phase and M phase in the cell cycle , 1994, Cell.
[423] C. Sherr. G1 phase progression: Cycling on cue , 1994, Cell.
[424] C. James,et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. , 1994, Cancer research.
[425] M. Pagano,et al. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. , 1994, Cancer research.
[426] A. Okamoto,et al. Mutations and altered expression of p16INK4 in human cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[427] O. Olopade,et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.
[428] D. Louis,et al. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. , 1994, Cancer research.
[429] K. Tanaka,et al. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. , 1994, Blood.
[430] Ashutosh Kumar Singh,et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. , 1994, Cancer research.
[431] D. Louis,et al. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. , 1994, Human molecular genetics.
[432] A. Klein-Szanto,et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. , 1994, Cancer research.
[433] L. Clark,et al. Loss of heterozygosity of chromosome 9p21 is associated with the immortal phenotype of neoplastic human head and neck keratinocytes. , 1994, Cancer research.
[434] T. Sugimura,et al. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. , 1994, Biochemical and biophysical research communications.
[435] Gregory J. Hannon,et al. pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.
[436] M. Knowles,et al. Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA. , 1994, Oncogene.
[437] W. Clark,et al. Germline p16 mutations in familial melanoma , 1994, Nature Genetics.
[438] R. Hruban,et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.
[439] M. Skolnick,et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.
[440] M. Ogawa,et al. Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. , 1994, Biochemical and biophysical research communications.
[441] M H Skolnick,et al. Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[442] M. You,et al. Deletion mapping of a putative tumor suppressor gene on chromosome 4 in mouse lung tumors. , 1994, Cancer research.
[443] L. Bonetta. Open questions on p16 , 1994, Nature.
[444] Peter A. Jones,et al. P16 gene in uncultured tumours , 1994, Nature.
[445] D. Sidransky,et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. , 1994, Science.
[446] G. Chenevix-Trench,et al. Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors. , 1994, American journal of human genetics.
[447] S. Mori,et al. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. , 1994, Cancer research.
[448] M. Knowles,et al. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. , 1994, Oncogene.
[449] J. Marx. A challenge to p16 gene as a major tumor suppressor. , 1994, Science.
[450] N. Nishida,et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. , 1994, Cancer research.
[451] K. Ichimura,et al. A Common Region of Homozygous Deletion in Malignant Human Gliomas Lies between the IFNα/ω Gene Cluster and the D9S171 Locus , 1994 .
[452] D. Elder,et al. Chromosome 9 deletion in sporadic and familial melanomas in vivo. , 1994, Oncogene.
[453] C. Cordon-Cardo,et al. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. , 1994, Cancer research.
[454] J. Bartek,et al. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1 , 1994, The Journal of cell biology.
[455] S. Baylin,et al. Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. , 1994, Cancer research.
[456] L. Campbell,et al. Homozygous and hemizygous deletions of 9p centromeric to the interferon genes in lung cancer. , 1994, Cancer research.
[457] G. Mann,et al. Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma. , 1994, Oncogene.
[458] E. Lander,et al. Allelotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3F1 mice: frequent losses of heterozygosity in regions homologous to human tumor-suppressor genes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[459] D. Carson,et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.
[460] O. Olopade,et al. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. , 1994, Cancer research.
[461] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[462] D. Sidransky,et al. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. , 1994, Cancer research.
[463] E. Harlow,et al. Identification of G1 kinase activity for cdk6, a novel cyclin D partner , 1994, Molecular and cellular biology.
[464] W. Clark,et al. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. , 1994, American journal of human genetics.
[465] R. Hruban,et al. Allelotype of head and neck squamous cell carcinoma. , 1994, Cancer research.
[466] J. R. Smith,et al. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. , 1994, Experimental cell research.
[467] R. Hruban,et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. , 1994, Cancer research.
[468] O. Olopade,et al. Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia. , 1994, Cancer research.
[469] G. Peters. The D-type cyclins and their role in tumorigenesis , 1994, Journal of Cell Science.
[470] S. van den Heuvel,et al. Distinct roles for cyclin-dependent kinases in cell cycle control. , 1993, Science.
[471] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[472] P. Bork. Hundreds of ankyrin‐like repeats in functionally diverse proteins: Mobile modules that cross phyla horizontally? , 1993, Proteins.
[473] D. Sidransky,et al. Evidence for two bladder cancer suppressor loci on human chromosome 9. , 1993, Cancer research.
[474] J. Weber,et al. Confirmation of chromosome 9p linkage in familial melanoma. , 1993, American journal of human genetics.
[475] S. Lerner,et al. Role of chromosome 9 in human bladder cancer. , 1993, Cancer research.
[476] J. Tomaszewski,et al. Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay. , 1993, Human molecular genetics.
[477] V. P. Collins,et al. Localization of chromosome 9p homozygous deletions in glioma cell lines with markers constituting a continuous linkage group. , 1993, Cancer research.
[478] D. Beach,et al. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. , 1993, Genes & development.
[479] S. Shurtleff,et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. , 1993, Genes & development.
[480] J. Weber,et al. Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of naevus count. , 1993, Melanoma research.
[481] D. Housman,et al. Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s). , 1993, American journal of human genetics.
[482] David M. Livingston,et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins , 1993, Cell.
[483] M. Pagano,et al. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. , 1993, Genes & development.
[484] O. Garson,et al. Molecular deletion of 9p sequences in non‐small cell lung cancer and malignant mesothelioma , 1993, Genes, chromosomes & cancer.
[485] M. Ewen,et al. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. , 1993, Genes & development.
[486] F. C. Lucibello,et al. Human cyclin D1 encodes a labile nuclear protein whose synthesis is directly induced by growth factors and suppressed by cyclic AMP. , 1993, Journal of cell science.
[487] M. Skolnick,et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. , 1992, Science.
[488] J. Kirkwood,et al. Homozygous deletions within human chromosome band 9p21 in melanoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[489] Steven K. Hanks,et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins , 1992, Cell.
[490] O. Olopade,et al. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. , 1992, Genomics.
[491] D. Housman,et al. Genetic and physical map of the interferon region on chromosome 9p. , 1992, Genomics.
[492] A. Knudson,et al. Localization of the interferon-α gene cluster to rat chromosome bands 5q31→q33 by fluorescence in situ hybridization , 1992 .
[493] O. Olopade,et al. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. , 1992, Cancer research.
[494] A. Godwin,et al. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. , 1992, Journal of the National Cancer Institute.
[495] J. Shay,et al. A role for both RB and p53 in the regulation of human cellular senescence. , 1991, Experimental cell research.
[496] A. Knudson,et al. Hereditary renal cell carcinoma in the rat associated with nonrandom loss of chromosomes 5 and 6. , 1991, Cancer research.
[497] T. Waltz,et al. Absence of methylthioadenosine phosphorylase in human gliomas. , 1991, Cancer research.
[498] S. Goldstein. Replicative senescence: the human fibroblast comes of age. , 1990, Science.
[499] L. Irving,et al. Cytogenetics of non‐small cell lung cancer: Analysis of consistent non‐random abnormalities , 1990, Genes, chromosomes & cancer.
[500] M. Genet,et al. Assignment of 12 loci to rat chromosome 5: evidence that this chromosome is homologous to mouse chromosome 4 and to human chromosomes 9 and 1 (1p arm). , 1990, Genomics.
[501] J. Allalunis-Turner,et al. Absence of IFNA and IFNB genes from human malignant glioma cell lines and lack of correlation with cellular sensitivity to interferons. , 1990, Cancer research.
[502] R. Larson,et al. Deletions of interferon genes in acute lymphoblastic leukemia. , 1990, The New England journal of medicine.
[503] A. Pardee. G1 events and regulation of cell proliferation. , 1989, Science.
[504] G. Levan,et al. A gene for the suppression of anchorage independence is located in rat chromosome 5 bands q22-23, and the rat alpha-interferon locus maps at the same region. , 1989, Journal of cell science.
[505] U. Francke,et al. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. , 1988, Journal of the National Cancer Institute.
[506] J. Rowley,et al. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[507] H. Harris. The Analysis of Malignancy by Cell Fusion: the Position in Updated Version Citing Articles E-mail Alerts , 2013 .
[508] J. Mosca,et al. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis , 1986, Molecular and cellular biology.
[509] A. Bird. CpG-rich islands and the function of DNA methylation , 1986, Nature.
[510] R. Eddy,et al. Assignment of the gene for methylthioadenosine phosphorylase to human chromosome 9 by mouse-human somatic cell hybridization. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[511] A. Sandberg,et al. A possible subgroup of ALL with 9p-. , 1983, Cancer genetics and cytogenetics.
[512] N. Kamatani,et al. Deficiency of methylthioadenosine phosphorylase in human leukemic cells in vivo. , 1982, Blood.
[513] J. Trent,et al. Chromosomal localization of human leukocyte, fibroblast, and immune interferon genes by means of in situ hybridization. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[514] W. Rutter,et al. Leukocyte and fibroblast interferon genes are located on human chromosome 9. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[515] S. Povey,et al. The analysis of malignancy by cell fusion. VII. Cytogenetic analysis of hybrids between malignant and diploid cells and of tumours derived from them. , 1977, Journal of cell science.
[516] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[517] L. Hayflick. THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. , 1965, Experimental cell research.
[518] R. Marmorstein,et al. Crystal structure of the CDK4/6 inhibitory protein p18INK4c provides insights into ankyrin-like repeat structure/function and tumor-derived p16INK4 mutations , 1998, Nature Structural Biology.
[519] A. Sober,et al. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. , 1998, Cancer research.
[520] E. Campo,et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.
[521] S. Lippman,et al. Frequent inactivation of p16INK4a in oral premalignant lesions , 1997, Oncogene.
[522] W. Franklin,et al. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. , 1997, Cancer research.
[523] T. Sano,et al. Infrequent mutations of p16INK4A and p15INK4B genes in human pituitary adenomas. , 1997, European journal of endocrinology.
[524] K. Ichimura,et al. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. , 1997, British journal of cancer.
[525] M. Roussel,et al. Features of macrophage differentiation induced by p19INK4d, a specific inhibitor of cyclin D-dependent kinases. , 1997, Blood.
[526] A. Takaoka,et al. Infrequent alterations of the p16 (MTS-1) gene in human gastric cancer. , 1997, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[527] J. Yokota,et al. Growth suppression of non-small cell lung carcinoma cells by the introduction of the p16(INK4A) gene. , 1997, International journal of oncology.
[528] J. Bartek,et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin’s lymphomas. Functional studies in a cell line (Granta 519) , 1997, Leukemia.
[529] S. Belinsky,et al. Deletion and differential expression of p16INK4a in mouse lung tumors. , 1997, Carcinogenesis.
[530] M. Fey,et al. Expression and regulation of G1 cell-cycle inhibitors (p16INK4A , p15INK4B, p18 INK4C, p19INK4D ) in human acute myeloid leukemia and normal myeloid cells , 1997, Leukemia.
[531] D. Louis,et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.
[532] N. Hayward,et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.
[533] D. Louis,et al. Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas , 1996, Acta Neuropathologica.
[534] T. Yoneda,et al. Comparative analysis of p16/CDKN2, p53 and ras gene alterations in human non-small cell lung cancers, with and without associated pulmonary asbestosis. , 1996, International journal of oncology.
[535] T. Savarese,et al. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. , 1996, Cancer genetics and cytogenetics.
[536] H. Koeffler,et al. p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[537] C. O'keefe,et al. Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4. , 1996, Molecular biology of the cell.
[538] Dracopoli Nc,et al. CDKN2 mutations in melanoma. , 1996 .
[539] M. You,et al. The 5′-flanking region of the E1 α form of the murine p16INK4a (MTS1) gene ☆ , 1996 .
[540] G. Peters,et al. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. , 1996, Advances in cancer research.
[541] P. Ambros,et al. Loss of the p16/MTS1 tumor suppressor gene causes E2F-mediated deregulation of essential enzymes of the DNA precursor metabolism. , 1996, DNA and cell biology.
[542] N. Konishi,et al. Detection of RB, p16/CDKN2 and p15(INK4B) gene alterations with immunohistochemical studies in human prostate carcinomas. , 1996, International journal of oncology.
[543] S. Bohlander,et al. TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines. , 1996, Blood.
[544] P. Zhao,et al. Abnormal location of p16 protein and overexpression of p53 protein in human radiation-induced skin cancer. , 1995, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.
[545] S. Povey,et al. Comparative mapping of 50 human chromosome 9 loci in the laboratory mouse. , 1995, Genomics.
[546] Y. Ishii,et al. A Case of Malignant Mesothelioma with Abnormal CDKN2 Gene Accompanied by Malignant Melanoma. , 1995 .
[547] T. Shuin,et al. Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers. , 1995, Oncology research.
[548] E. Lees. Cyclin dependent kinase regulation. , 1995, Current opinion in cell biology.
[549] A. Kaye,et al. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. , 1995, Cancer research.
[550] F. Kaye,et al. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. , 1994, Oncogene.
[551] A. Knudson,et al. Spontaneous and radiation-induced renal tumors in the Eker rat model of dominantly inherited cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[552] H. Klinger. Suppression of tumorigenicity. , 1982, Cytogenetics and cell genetics.